GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Essex Bio-Technology Ltd (HKSE:01061) » Definitions » ROC %

Essex Bio-Technology (HKSE:01061) ROC % : 13.73% (As of Jun. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Essex Bio-Technology ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Essex Bio-Technology's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was 13.73%.

As of today (2025-03-30), Essex Bio-Technology's WACC % is 5.89%. Essex Bio-Technology's ROC % is 11.82% (calculated using TTM income statement data). Essex Bio-Technology generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Essex Bio-Technology ROC % Historical Data

The historical data trend for Essex Bio-Technology's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Essex Bio-Technology ROC % Chart

Essex Bio-Technology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.33 15.23 23.54 14.44 14.03

Essex Bio-Technology Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.41 13.94 17.97 10.11 13.73

Essex Bio-Technology ROC % Calculation

Essex Bio-Technology's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=311.681 * ( 1 - 20.45% )/( (1715.601 + 1819.841)/ 2 )
=247.9422355/1767.721
=14.03 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2712.397 - 453.304 - ( 543.492 - max(0, 560.917 - 1213.978+543.492))
=1715.601

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2827.558 - 573.183 - ( 515.025 - max(0, 810.744 - 1245.278+515.025))
=1819.841

Essex Bio-Technology's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=349.606 * ( 1 - 20.24% )/( (1819.841 + 2241.774)/ 2 )
=278.8457456/2030.8075
=13.73 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2827.558 - 573.183 - ( 515.025 - max(0, 810.744 - 1245.278+515.025))
=1819.841

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2965.806 - 160.602 - ( 600.618 - max(0, 824.204 - 1387.634+600.618))
=2241.774

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Essex Bio-Technology  (HKSE:01061) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Essex Bio-Technology's WACC % is 5.89%. Essex Bio-Technology's ROC % is 11.82% (calculated using TTM income statement data). Essex Bio-Technology generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Essex Bio-Technology ROC % Related Terms

Thank you for viewing the detailed overview of Essex Bio-Technology's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Essex Bio-Technology Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.
Executives
Lauw Hui Kian
Ngiam Mia Je Patrick
Ngiam Mia Kiat Benjamin 2101 Beneficial owner

Essex Bio-Technology Headlines

No Headlines